basaloid cell
Recently Published Documents


TOTAL DOCUMENTS

26
(FIVE YEARS 1)

H-INDEX

8
(FIVE YEARS 0)

2021 ◽  
Vol 4 (3) ◽  
pp. 179-183
Author(s):  
Lewkowicz Milagros ◽  
Greco Alejandro ◽  
Lezcano Gabriel ◽  
Cachau Victoria ◽  
Díaz Florencia

Pilomatrical Carcinoma (PC) is a rare malignant adnexal tumor with matrical differentiation. Its benign counterpart (Pilomatrixoma) is diagnosed much more frequently in daily pathological practice. Both entities share genetic alterations but the malignant counterpart acquires mutations that make it develop an aggressive behavior [1]. We describe a 33-year-old man who presented with a 7 x 6 cm nodular ulcerated lesion in the left ear with markedly accelerated growth in the last month. Incisional biopsy was referred to us with suspicion of squamous cell carcinoma versus pyogenic granuloma. Histologic sections showed ulcerated fragments infiltrated by a basaloid cell proliferation interspersed with groups of “ghost cells”. The neoplastic cells were arranged in irregular sheets with infiltrative borders. Groups of Squamous cells with trichilemmal keratinization and foci of necrosis were also identified. The biopsy was diagnosed as an adnexal neoplasm with pilomatrical differentiation, suggesting its complete resection with safety margins due to the presence of aggressive characteristics. The subsequent study of the excisional biopsy showed similar characteristics to those previously described. Notoriously, focal infiltration of the auricular cartilage was identified, leading us to the undoubted diagnosis of pilomatrical carcinoma.


2020 ◽  
Author(s):  
Keyword(s):  

2019 ◽  
Vol 2019 (8) ◽  
Author(s):  
Leilei Shen ◽  
Jixing Lin ◽  
Zhipeng Ren ◽  
Bailin Wang ◽  
Kai Zhao ◽  
...  

Abstract Ciliated muconodular papillary tumor (CMPT) is a peripheral non-endobronchial lung nodule, consisting of ciliated columnar cells and goblet cells with basaloid cell proliferation. Only about 50 cases confirmed by surgery have been reported in English literature worldwide. We present two surgical cases of CMPT in this report. Two patients presented with abnormal computed tomography findings but no obvious symptoms. The first patient’s intraoperative frozen examination was unable to distinguish benignity from malignancy, and he received lobectomy. The other patient’s intraoperative frozen examination indicated adenocarcinoma, but she received wedge resection for her refusal to lobectomy. The two patients’ postoperative pathological analysis finally confirmed the diagnosis of CMPT. We believe that our cases may be essential for pathologists and surgeons to improve their understanding.


2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 7-7 ◽  
Author(s):  
Ken Kato ◽  
Hiroyasu Igaki ◽  
Yoshinori Ito ◽  
Isao Nozaki ◽  
Hiroyuki Daiko ◽  
...  

7 Background: Esophagectomy (E) is the standard of care for stage I esophageal squamous cell carcinoma (ESCC), while chemoradiotherapy (CRT) is a treatment option. A parallel-group controlled trial including randomized arms to confirm the non-inferiority of CRT to E for stage IA ESCC was conducted. Methods: Patients (pts) with thoracic ESCC, adenosquamous cell, or basaloid cell carcinoma with stage IA (T1bN0M0), age 20 to 75, performance status 0 to 1, and adequate organ function were eligible. If pts accepted randomization, they were randomly allocated to E with 2-3 field lymph node dissection (arm A) or CRT (arm B). However, if pts had a preference and refused randomization, they were allocated to pts preference arm, E (arm C) or CRT (arm D). CRT consisted of cisplatin and 5-FU, with radiation at the dose of 60 Gy concurrently. The primary endpoint was overall survival (OS) of arm A and B, secondary endpoint included OS of arm C and D using inverse probability weighting with propensity score. The planned sample size in arm A and B was 114 pts in total with one-sided alpha of 10%, power of 75% and non-inferiority margin of HR as 1.78. The sample size in arm C and D was at least 156 pts in each arm with one-sided alpha of 2.5%, power of 85% and non-inferiority margin of HR as 1.78. Results: Between December 2006 and February 2013, 379 (Arm A: 4, B: 7, C: 209 C, D: 159) pts were enrolled. Primary endpoint was not calculated due to small number of randomized arms. Patients characteristics of arm C and D were as follows; median age: 62 and 65, male (%): 82.8 and 88.1, PS 0 (%): 99.5 and D 98.1. All histologic type was SCC except one basaloid cell carcinoma in arm C. The 3- and 5-year OS were 94.7% and 86.5% in arm C, and 93.1% and 85.5% in arm D (adjusted HR 1.05; 95% CI 0.67-1.64 [< 1.78]).Treatment related death were observed in two pts in arm C and none in arm D. Conclusions: Though the accrual of randomized arms was shortened, CRT showed trend toward non-inferiority compared to E in pts preference arms. CRT is considered as a treatment option for stage IA ESCC with organ preservation. Clinical trial information: UMIN000000551.


2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 188-188
Author(s):  
Marta De Vega ◽  
Carlos Miliani ◽  
Juan Rodriguez Vitoria ◽  
Juan Antonio Martinez-Piñeiro ◽  
Fernando Pereira

Abstract Background Basaloid cell carcinoma of the esophagus (BSCCE) is a rare (0.07–4%) poorly-differentiated variety of squamous cell carcinoma (SCC), more aggressive and with a worse prognosis than typical SCC. There are no published studies on the best therapeutic option for these tumors or on of the effectiveness of Neoadjuvant chemoradiotherapie; so there is no standard treatment. We describe the characteristics and the therapeutic strategy applied to a patient with an avanced basaloid squamous cell carcinoma of the distal esophagus. Methods A 70-year-old woman with dysphagia and severe malnutrition was diagnosed with locally advanced esophageal cáncer of lower esophagus The biopsy indicated moderately differentiated basaloid cell carcinoma. The clinical diagnosis was cT4NxM0, We decided multimodal treatment with curative intent: Neoadjuvant chemoradiotherapie at a dose of 41.4 Gy and concomitant carboplatin and pacliotaxel 5 cycles (CROSS scheme) plus surgery. Results PET-TAC post-neoadjuvant re-evaluation showed partial morphological response (reduction of tumor metabolism in 34.7%). 6 weeks after radiochemotherapy we performed a three fields total esophagectomy. Postoperative course without incidents. The pathological diagnosis was BASALOID cell CARCINOMA located in distal esophagus of 10 cm long with 30% tumor residual; it affects gastro-oesophageal junction. Stage TNM 7th ed: ypT3 N0 (0/17) L0V1R0 Our patient is fine and without evidence of recurrence after 15 meses. Conclusion Basal squamous cell carcinoma is more common in men around 60 years old, being rare in older women. They are located more frequently in the middle than in lower esophagus. They are tumors of poor prognosis (poorly differentiated, locally advanced and with an aggressive biological behavior that predisposes to early metastasis) although the latest publications relate the prognosis especially with the stage of the tumor. There are no published data about the use of Neoadjuvant treatment for these tumors. We have carried out a multimodal treatment (Cross scheme) followed by surgery with clinical, radiological (PET-TAC) and pathological response (30% of residual tumor in the piece) CONCLUSION The multimodal treatment with Cross scheme and surgery was useful in patients with Basaloid tumor of the esophagus can be considered for patients with this type of tumor. Disclosure All authors have declared no conflicts of interest.


2016 ◽  
Vol 24 (2) ◽  
pp. 42-46
Author(s):  
Takeshi Shimakawa ◽  
Yoshihiko Naritaka ◽  
Miki Miyazawa ◽  
Asako Shimazaki ◽  
Shinichi Asaka ◽  
...  

2014 ◽  
Vol 140 (0) ◽  
pp. 100-101
Author(s):  
Tsuyoshi Takemoto ◽  
Kenji Takeno
Keyword(s):  

2014 ◽  
Vol 107 (3) ◽  
pp. 247-250
Author(s):  
Tsuyoshi Takemoto ◽  
Kenji Takeno
Keyword(s):  

2013 ◽  
Vol 74 (6) ◽  
pp. 1488-1494 ◽  
Author(s):  
Yoko SANDA ◽  
Kunihiko KANEDA ◽  
Yukiko MIURA ◽  
Shunji NAKAYAMA ◽  
Katsunori KAWAGUCHI

Sign in / Sign up

Export Citation Format

Share Document